Phase II Trial Reports Anticancer Activity With Novel FGFR Inhibitor in Advanced Intrahepatic Cholangiocarcinoma

Futibatinib—a selective, fibroblast growth factor receptor (FGFR) inhibitor—demonstrated anticancer activity in patients with advanced intrahepatic cholangiocarcinoma and FGFR2 fusions or rearrangements. These findings are based on the primary results of the phase II FOENIX-CCA2 trial, which were reported by Lipika Goyal, MD, and colleagues during the virtual edition of the American Association for Cancer Research Annual Meeting 2021.

Relationship Between Germline BRCA Pathogenic Variants and Diminished Ovarian Reserve

In a study reported in the Journal of Clinical Oncology, Turan et al found the presence of germline BRCA pathogenic variants was associated with diminished ovarian reserve in young women, particularly in those diagnosed with breast cancer and those with BRCA1 variants.

Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity

In a health system retrospective study reported in JCO Oncology Practice, Nhean et al found that implementation of an oral chemotherapy management program was associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related emergency department visits and hospitalization, and improved drug adherence.